Share >  
Share
Share on Tumblr

Intas Pharmaceuticals

News »

   latest by relevance
Larger product pipeline, bigger footprint: Rel Lifesciences
Nov 08, 2011 at 22:23 | Source: CNBC-TV18
Faced with close competition from Dr Reddy's, Intas Pharma and Biocon, Reliance Lifesciences strategy to stand out is by offering the largest product pipeline in biosimilars. The Mukesh Ambani-led company is betting on non-insulin biosimilars to enlarge its footprint in India and emerging markets.
ICRA assigns grade 4 to Intas Pharmaceuticals IPO
Jul 27, 2011 at 17:45 | Source: Moneycontrol.com
ICRA has assigned a grade 4 to the proposed IPO of Intas Pharmaceuticals (IPL), indicating above average fundamentals, in its research report.
ChrysCap selling major chunk in Intas Pharma IPO
Mar 29, 2011 at 13:09 | Source: VCCircle
ChrysCapital is selling half of its holding in Intas Pharmaceuticals in the public issue of the mid-sized drug-maker that is looking to raise Rs 425 crore through fresh issue of shares during the IPO.
Intas Pharmaceuticals files DRHP for IPO
Mar 28, 2011 at 17:09 | Source: Moneycontrol.com
Intas Pharmaceuticals, has filed its draft red herring prospectus (DRHP) with Securities and Exchange Board of India (SEBI) for an initial public offering (IPO) of its equity shares of face value Rs 10 each comprising a fresh issue of equity shares aggregating up to Rs 425 crore and an offer for sale of 5,810,550 equity shares by Mozart Limited.
IBPL- Apotex to develop biosimilar version of pegfilgrastim
Feb 06, 2009 at 16:18
Apotex Inc. of Canada and Intas Biopharmaceuticals Limited of India have extended their business agreement to develop a biosimilar version of pegfilgrastim, a protein that is used to treat neutropenia (a side effect of cancer chemotherapy).
Intas Biopharma & Kwizda complete clinical trial of Neukine
Apr 09, 2008 at 15:35
Intas Biopharmaceuticals Limited (IBPL) and European pharmaceutical major Kwizda Pharma GmbH has jointly completed Phase I clinical trial study of Neukine, biosimilar form of recombinant GCSF

Videos »
Larger product pipeline, bigger footprint: Rel Lifesciences
more »

Photos »

  /  
Interact & exchange stock tips & market info »

Web Messenger

Platinum Member

107770 Followers

News Now  

Source:Economic Times - NEW DELHI: Private equity firm ChrysCapital i...

12.58 PM Apr 26th

Web Messenger

Platinum Member

107770 Followers

News Now  

Source:Economic Times - Private equity firm ChrysCapital is buying an...

10.57 AM Apr 26th

Web Messenger

Platinum Member

107770 Followers

News Now  

Source:VC Circle - BY TEAM VCC Intas has deferred its IPO where it pla...

10.10 AM Apr 26th

Related News »
Biopharmaceutical Licensing Market - Global Industry Size, Market Share, Trends, Analysis,
Key players dominating this industry are Intas Pharmaceuticals Ltd., Pfizer, Merck & Co., GlaxoSmithKline, Johnson & Johnson, Bayer AG, Novartis, Hoffman La-Roche, Sanofi, AstraZeneca, Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly & Company ...
May 22, 2012 at 10:02 | Source: PRLog (free press release)
Tano Capital Increases Its Stake In Shilpa Medicare
Italy (ICE) and Prodotti Chini Alimetari SpA, Italy (PCA) for undertaking contract manufacturing. Recently, ChrysCapital invested additional R300Cr in Intas Pharmaceuticals increasing its stake from 11.3% to over 15%.
May 23, 2012 at 05:50 | Source: dealcurry.com
Tano Capital Invests R9.79Cr In Shilpa Medicare
It bought 2 Mn shares for around Rs.350 per share. Recently, ChrysCapital invested additional R300Cr in Intas Pharmaceuticals increasing its stake from 11.3% to over 15%.
May 16, 2012 at 06:27 | Source: dealcurry.com

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window